Protagonist Therapeutics (NASDAQ: PTGX) saw a nearly 30% increase in its stock price on Friday due to takeover speculation, with Johnson & Johnson rumored to be in talks to acquire the biotech company. Despite a down day for stocks, Protagonist’s stock soared, thanks to positive clinical trial results. Both companies have yet to comment on the potential deal, but investors should keep an eye on developments. The Motley Fool’s Stock Advisor team has not included Protagonist Therapeutics in their list of top 10 stocks to buy now, highlighting the uncertainty surrounding the rumored acquisition.

Read more at Nasdaq: Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today